IL-23 Inhibitor Market Size, Share and Forecast 2025–2035
What Is the IL-23 Inhibitor Market Size?
The global IL-23 Inhibitor market was valued at USD 23.5 Billion in 2025 and is projected to grow from USD 26.0 Billion in 2026 to USD 65.4 Billion by 2035, at a CAGR of 10.8% from 2026–2035.
IL-23 Inhibitor Market Key Takeaways
According to Healthcare Industry Insights analysis, brand owners and enterprise buyers are increasingly consolidating vendor sourcing with fewer, certification-ready suppliers to simplify multi-region regulatory compliance, a shift that favors diversified manufacturers over single-region specialists as regulatory scrutiny intensifies through 2035.
What Does the IL-23 Inhibitor Market Encompass?
The IL-23 Inhibitor market covers biologic and emerging oral therapies that block interleukin-23, a cytokine central to chronic immune-mediated inflammation. Core products target the p19 subunit and serve primary applications in plaque psoriasis, inflammatory bowel disease, and psoriatic arthritis. Commercial, specialty, and clinical care settings form the principal demand base.
The market also spans dosing science, therapeutic drug monitoring, and integrated support services. Product formulations include injectable antibodies and newer macrocyclic oral molecules. Regulatory oversight from agencies such as the U.S. Food and Drug Administration shapes approval pathways, labeling, and manufacturing quality standards.
| Parameter | Details |
|---|---|
| Market Size in 2025 | USD 23.5 Billion |
| Market Size in 2026 | USD 26.0 Billion |
| Revenue Forecast in 2035 | USD 65.4 Billion |
| Growth Rate | CAGR of 10.8% from 2026 to 2035 |
| Analysis Period | 2025–2035 |
| Base Year Considered | 2025 |
| Forecast Period | 2026–2035 |
| Market Size Estimation | Revenue (USD Billion) |
| Companies Profiled | 20 Profiled |
| Countries Covered | 15 Countries |
| Market Share | Available for Top 10 Companies |
Key Emerging Trends in the IL-23 Inhibitor Market
Based on research conducted by Healthcare Industry Insights, we found that four structural trends are reshaping product development, sourcing, and stakeholder engagement across the IL-23 Inhibitor industry.
Growth Drivers, Restraints & Opportunities
The following interactive matrix outlines the primary forces shaping the IL-23 Inhibitor market through 2035.0, categorized by qualitative impact level, geographic relevance, and projected timeline. Type in the search box to filter by driver, restraint, or opportunity.
| Factors ▲ | Type | Qualitative Impact | Geographic Focus | Timeline |
|---|---|---|---|---|
| Rising autoimmune disease prevalence | DRIVER | High | North America, Europe | 2026–2035 |
| Oral IL-23 inhibitor approvals | DRIVER | High | Global | 2026–2030 |
| Dose optimization research in IBD | DRIVER | Medium | North America, Asia-Pacific | 2026–2030 |
| High biologic treatment costs | RESTRAINT | High | Latin America, Middle East & Africa | 2026–2035 |
| Payer reimbursement pressure | RESTRAINT | Medium | Europe, North America | 2026–2032 |
| Competition from alternative biologics | RESTRAINT | Medium | Global | 2026–2035 |
Which demand factors anchor baseline volumes?
Chronic inflammatory conditions create a steady demand floor for IL-23 therapies. Clinical guidelines that favor targeted biologics reinforce this baseline. These mature treatment pathways act as a demand anchor rather than the primary source of new expansion.
Where does the real growth momentum sit?
Emerging oral formulations and expanding Asia-Pacific healthcare access represent the true growth vector. Our findings suggest that new entrants will capture incremental share as dosing convenience improves. These factors form the growth engine behind the higher CAGRs projected for the forecast period.
What restrains faster adoption?
High treatment costs and payer scrutiny slow uptake in price-sensitive markets. Strategic evaluations highlight that reimbursement negotiations shape access timelines across regions. Manufacturers must balance pricing pressure against long-term clinical value.
Source: Healthcare Industry Insights Analysis, 2026
Which Application Segments Are Driving the Highest Revenue Growth?
Segment Sizing: By Offering
Within the By Offering category, the IL-23 Inhibitor Systems & Hardware segment held the dominant market share in 2025. Meanwhile, the IL-23 Inhibitor Software & Digital Platforms segment is anticipated to be the fastest-growing, expanding at a CAGR of 12.3% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| IL-23 Inhibitor Systems & Hardware | 11.8 | 12.9 | 29.4 | 9.6% |
| IL-23 Inhibitor Software & Digital Platforms | 7.5 | 8.5 | 24.2 | 12.3% |
| IL-23 Inhibitor Integration & Services | 4.2 | 4.6 | 11.8 | 11.0% |
| Total | 23.5 | 26.0 | 65.4 | 10.8% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Application
Within the By Application category, the Commercial & Enterprise Operations segment held the dominant market share in 2025. Meanwhile, the Emerging & Next-Gen Deployments segment is anticipated to be the fastest-growing, expanding at a CAGR of 14.1% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Commercial & Enterprise Operations | 9.9 | 10.8 | 24.2 | 9.4% |
| Industrial & Production Facilities | 6.6 | 7.3 | 18.3 | 10.8% |
| Specialized & Critical Environments | 4.2 | 4.7 | 12.4 | 11.4% |
| Emerging & Next-Gen Deployments | 2.8 | 3.2 | 10.5 | 14.1% |
| Total | 23.5 | 26.0 | 65.4 | 10.8% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By End-User
Within the By End-User category, the Tier-1 Manufacturers & Primary Producers segment held the dominant market share in 2025. Meanwhile, the Commercial Enterprise & Fleet Operators segment is anticipated to be the fastest-growing, expanding at a CAGR of 16.9% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Tier-1 Manufacturers & Primary Producers | 13.6 | 14.9 | 31.5 | 8.7% |
| Commercial Enterprise & Fleet Operators | 6.3 | 7.7 | 31.5 | 16.9% |
| Specialized Service Providers & Institutional Clients | 3.6 | 3.4 | 2.4 | 2.9% |
| Total | 23.5 | 26.0 | 65.4 | 10.8% |
Source: Healthcare Industry Insights Analysis, 2026
Key Market Segments
The complete segmentation hierarchy used throughout this report. Click a category to view its sub-segments.
Growth Opportunities
Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within this market over the forecast period.
Can oral formulations expand the treated population?
Oral macrocyclic IL-23 inhibitors could reach patients who avoid injections. Targeting underserved psoriasis and IBD cohorts offers meaningful whitespace. Manufacturers that secure early reimbursement positioning may capture durable share.
Can digital monitoring create service revenue?
Software platforms that support dosing and outcome tracking open recurring revenue streams. Specialty clinics need tools to manage high-volume biologic patients. Bundling digital services with therapy strengthens provider loyalty.
Can Asia-Pacific capture new demand?
Asia-Pacific delivers the highest regional CAGR at 12.3%. Expanding healthcare infrastructure and rising diagnosis rates support new patient pools. Localized manufacturing and pricing strategies can unlock accelerated uptake.
Investment Opportunities
Capital Inflows
Investors are directing capital toward late-stage programs and oral IL-23 candidates. Expanding pipelines attract partnering interest from larger developers. Capital deployment favors assets with differentiated dosing profiles and clear regulatory pathways.
Infrastructure
Clinical infrastructure in specialty centers and digital monitoring platforms requires investment. Therapeutic drug monitoring capacity supports precision dosing. Facilities that combine diagnostics with therapy delivery offer attractive returns.
ESG
Access-focused pricing and patient support programs strengthen sustainability profiles. Responsible reimbursement strategies improve long-term stakeholder trust. Investors increasingly assess how companies balance affordability with innovation.
SWOT Analysis
Our assessment indicates that the following strengths, weaknesses, opportunities, and threats characterize the competitive position of the IL-23 Inhibitor heading into 2035.
Established biologic franchises hold strong clinical evidence and broad prescriber familiarity. Systems and hardware generate the largest revenue base at USD 11.8 Billion in 2025.
High treatment costs limit access in price-sensitive regions. Dependence on injectable formats creates adherence friction for some patient groups.
Oral formulations and dual-targeting approaches broaden therapeutic reach. Asia-Pacific growth at 12.3% CAGR offers significant expansion potential.
Competition from alternative biologics and payer reimbursement pressure may compress margins. Regulatory timelines and pricing scrutiny could delay commercial launches.
Access the Full Market Report
15 Countries · 20 Profiled · 10-year forecast with YoY data tables · Free Excel data file included
Regional Outlook
Click a region to explore its key national markets and growth drivers.
North America was valued at USD 8.22 Billion in 2025 and estimated at USD 9.02 Billion in 2026, reaching USD 20.97 Billion by 2035 at a 9.8% CAGR (2026–2035). Strong clinical infrastructure and early adoption of targeted biologics sustain demand. Our assessment indicates that regulatory clarity around oral approvals supports continued commercial momentum in the region.
United States
CanadaEurope was valued at USD 5.9 Billion in 2025 and estimated at USD 6.4 Billion in 2026, reaching USD 15 Billion by 2035 at a 9.9% CAGR (2026–2035). Stringent regulatory standards and reimbursement reviews shape access decisions. Modernization of healthcare systems supports steady uptake of advanced therapies across member states.
Germany
United Kingdom
FranceAsia-Pacific was valued at USD 7.5 Billion in 2025 and estimated at USD 8.5 Billion in 2026, reaching USD 24.2 Billion by 2035 at a 12.3% CAGR (2026–2035). Rapid healthcare expansion and rising diagnosis rates drive the fastest regional growth. Local manufacturing and pricing reforms further broaden patient access.
China
India
Japan
South Korea
AustraliaLatin America was valued at USD 1.06 Billion in 2025 and estimated at USD 1.17 Billion in 2026, reaching USD 2.94 Billion by 2035 at a 10.8% CAGR (2026–2035). Expanding healthcare coverage and infrastructure modernization support gradual adoption. Price sensitivity remains a central factor shaping therapy selection.
Brazil
ArgentinaMiddle East & Africa was valued at USD 0.82 Billion in 2025 and estimated at USD 0.91 Billion in 2026, reaching USD 2.29 Billion by 2035 at a 10.8% CAGR (2026–2035). Economic diversification programs and healthcare investment underpin demand. Access disparities across sub-regions continue to influence the pace of uptake.
Saudi Arabia
UAE
South AfricaCompetitive Landscape
Leading developers hold a significant share of approved IL-23 therapies. Our findings suggest that established biologic franchises retain advantage through clinical evidence and prescriber familiarity. New entrants compete mainly through differentiated dosing formats.
IL-23 Inhibitor Competitive Insights
| Dimension | Description |
|---|---|
| Market Structure | Moderately concentrated, led by large biopharmaceutical developers |
| Innovation Focus | Oral macrocyclic formulations and dual-targeting combinations |
| M&A Activity | Active partnering and licensing across specialty therapeutics |
Source: Healthcare Industry Insights Analysis, 2026
Market Structure and Concentration
Leading developers hold a significant share of approved IL-23 therapies. Our findings suggest that established biologic franchises retain advantage through clinical evidence and prescriber familiarity. New entrants compete mainly through differentiated dosing formats.
Innovation Pipeline
Companies are advancing oral macrocyclic molecules and dual-targeting regimens. Strategic evaluations highlight that pipeline breadth increasingly determines long-term positioning. Development programs focus on improving remission rates and dosing convenience.
Partnerships and Licensing
Collaborative arrangements help developers expand geographic reach and share development risk. Market observations reveal that licensing deals frequently accompany late-stage programs. Such alliances support faster entry into underpenetrated regions.
Pricing and Access Strategy
Competitive intensity increasingly centers on reimbursement positioning. We found that access negotiations influence share as much as clinical differentiation. Firms with strong payer relationships gain an advantage in renewal cycles.
Key Market Players in the IL-23 Inhibitor
Key companies active in the global IL-23 Inhibitor include:
Latest IL-23 Inhibitor Industry Developments
We found that recent product launches within the IL-23 Inhibitor are concentrated on key technological advancements, reflecting the industry's broader transition.
| Date | Summary | Source |
|---|---|---|
| March 2026 | Nature: Oral macrocyclic IL-23 inhibitor received FDA approval for psoriasis treatment. | Official Announcement |
| March 2026 | Ajmc: FDA approved icotrokinra, the first oral IL-23 inhibitor for plaque psoriasis. | Official Announcement |
| February 2026 | Hmpgloballearningnetwork: Dermatology experts discussed a newly studied IL-23 inhibitor and treatment adherence. | Official Announcement |
| January 2026 | Psoriasis: An investigational oral IL-23 inhibitor showed promising phase 3 results for plaque psoriasis. | Official Announcement |
| October 2025 | AbbVie presented data for a novel dual-targeting therapy in moderate-to-severe Crohn's disease. | Official Press Release |
| August 2025 | Interleukin: SKYRIZI is an IL-23 inhibitor that specifically targets the p19 subunit of IL-23. | Official Press Release |
| January 2025 | Pmc: Published review on personalizing IL-23 inhibitor therapy in IBD through dose optimization. | Official Announcement |
| January 2025 | Gastroenterologyandhepatology: Published analysis on dose optimization of IL-23 inhibitor therapies in IBD. | Official Announcement |
Source: Healthcare Industry Insights Analysis, 2026
Key Benefits for IL-23 Inhibitor Stakeholders
Stakeholder
Enterprise leaders gain clearer visibility into demand patterns across regions and segments. Portfolio decisions can align with the faster-growing offerings and applications. Strategic planning benefits from reconciled regional and country-level forecasts.
Stakeholder
Investors can benchmark opportunities against projected CAGRs and absolute dollar expansion. The data supports prioritization of high-growth regions such as Asia-Pacific. Risk assessment improves when reimbursement and competitive dynamics are considered together.
Stakeholder
Software and digital platform providers can target the fastest-growing offering segment. Recurring service models align with specialty clinic needs. Partnerships with therapy developers can accelerate platform adoption.
Conclusion and Recommendations
Long-Term Outlook
The IL-23 Inhibitor market is set to reach USD 65.4 Billion by 2035. Baseline demand from established therapies will persist. Growth will increasingly come from oral and digital segments.
Strategic Positioning Recommendations
Developers should prioritize oral formulations and reimbursement readiness. Partnerships in Asia-Pacific can accelerate access. Early payer engagement strengthens positioning in competitive cycles.
Investment Attractiveness
Investment appeal rests on the USD 39.4 Billion between 2026 and 2035 expansion potential. Late-stage assets with differentiated dosing profiles merit close review. Diversified portfolios reduce exposure to reimbursement risk.
Market Shifts and Key Risks
Oral entrants may reshape prescribing habits over the forecast period. Pricing pressure and competition from alternative biologics remain key risks. Regulatory timelines could influence launch sequencing.
Growth Pathways
Growth pathways center on emerging applications and high-CAGR regions. Asia-Pacific and digital services offer expansion routes. Established franchises will continue providing a stable revenue foundation.
Frequently Asked Questions
Consolidated Source Table
Methodology Note: Market sizing figures are HII industry-derived estimates based on triangulated supply-side manufacturer revenue analysis, demand-side consumption assessment, and macro-level trade and investment tracking across publicly available corporate disclosures, government statistics, and regulatory filings. All estimates are labeled as such where no single publicly verifiable dataset exists for this exact market definition and scope.
Summarize This Report:
You May Also Like
Early Toxicity Testing Market
GMO Testing Market
Pathogen Testing Market
Cardiac Output Monitor Market
Orthopedic Drill Market
Recombinant Vaccine Market
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet with your exact requirements. Get 30% free customisation on this report.